

V. TRIMETHAPHAN CAMSYLATE FOR INTRAVENOUS INFUSION

A. *Effectiveness classification.* The Food and Drug Administration has considered the Academy's report, as well as other available evidence, and concludes that this drug is effective for the production of controlled hypertension during surgery; for the short term (acute) control of blood pressure in hypertensive emergencies; in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.

B. *Form of drug.* Trimethaphan camsylate preparations are in sterile aqueous solution form, when diluted, for intravenous infusion.

C. *Labeling conditions.* 1. The label bears the statement, "Caution: Federal law prohibits dispensing without prescription."

2. The drug is labeled to comply with all requirements of the Act and regulations. Its labeling bears adequate information for safe and effective use of the drug and is in accord with the guidelines for uniform labeling published in the FEDERAL REGISTER of February 6, 1970. The "Indications" section is as follows:

INDICATIONS

For the production of controlled hypotension during surgery. For the short term (acute) control of blood pressure in hypertensive emergencies. In the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.

VI. MARKETING STATUS

Marketing of such drugs may be continued under the conditions described in the notice entitled "Conditions for Marketing New Drugs Evaluated in Drug Efficacy Study," published in the FEDERAL REGISTER, July 14, 1970 (35 F.R. 11273), as follows:

A. For holders of "deemed approved" new drug applications (i.e., an application which became effective on the basis of safety prior to October 10, 1962), the submission of a supplement for revised labeling, an abbreviated supplement for updating information, and adequate data to show the biologic availability of the drug, when administered other than by the intravenous route, in the formulation which is marketed, as described in paragraphs (a) (1) (i), (ii), and (iii) of the notice of July 14, 1970.

B. For any person who does not hold an approved or effective new drug application, the submission of an abbreviated new drug application, to include adequate data to assure the biologic availability of the drug in the formulation which is or is intended to be marketed for administration other than by the intravenous route, as described in paragraph (a) (3) (ii) of that notice.

C. For any distributor of the drug, the use of labeling in accord with this announcement for any such drug shipped within the jurisdiction of the Act as described in paragraph (b) of that notice.

VII. OPPORTUNITY FOR A HEARING

A. The Commissioner of Food and Drugs proposes to issue an order under the provisions of section 505(e) of the Federal Food, Drug, and Cosmetic Act withdrawing approval of all new drug applications and all amendments and supplements thereto providing for the indications for which substantial evidence of effectiveness is lacking as described in Paragraph I.A., and II.A. of this announcement. An order withdrawing approval of the applications will not issue if such applications are supplemented, in accord with this notice, to delete such indications. Promulgation of the proposed order would cause any related drug for human use offered for the indications for which substantial evidence of effectiveness is lacking to be a new drug for which an approved new drug application is not in effect. Any such drug then on the market would be subject to regulatory proceedings.

B. In accordance with the provisions of section 505 of the Act (21 U.S.C. 355) and the regulations promulgated thereunder (21 CFR Part 130), the Commissioner will give the holders of any such applications, and any interested person who would be adversely affected by such an order, an opportunity for a hearing to show why such indications should not be deleted from labeling. A request for a hearing must be filed within 30 days after the date of publication of this notice in the FEDERAL REGISTER.

C. A request for a hearing may not rest upon mere allegations or denials but must set forth specific facts showing that a genuine and substantial issue of fact requires a hearing, together with a well-organized and full-factual analysis of the clinical and other investigational data that the objector is prepared to prove in a hearing. Any data submitted in response to this notice must be previously unsubmitted and include data from adequate and well-controlled clinical investigations (identified for ready review) as described in § 130.12(a) (5) of the regulations published in the FEDERAL REGISTER of May 8, 1970 (35 F.R. 7250). Carefully conducted and documented clinical studies obtained under uncontrolled or partially controlled situations are not acceptable as a sole basis for approval of claims of effectiveness, but such studies may be considered on their merits for corroborative support of efficacy and evidence of safety.

D. A hearing is requested and is justified by the response to this notice, the issues will be defined, a hearing examiner will be named, and he shall issue a written notice of the time and place at which the hearing will commence.

A copy of the Academy's report has been furnished to each firm referred to above. Any other interested person may obtain a copy by request to the Food and Drug Administration, Press Relations Office (CE-200), 200 C Street SW., Washington, D.C. 20204.

Communications forwarded in response to this announcement should be

identified with the reference number DESI 8983, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20852:

Supplements (identify with NDA number):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.

Original abbreviated new drug applications (identify as such): Drug Efficacy Study Implementation Project Office (BD-5),
Bureau of Drugs.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs.

This notice is issued pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: May 25, 1971.

SAM D. FINE,
Associate Commissioner
for Compliance.

[FR Doc. 71-8718 Filed 6-21-71; 8:46 am]

[DESI 60105]

PENICILLIN FOR INHALATION

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated a report received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on Penicillin G Potassium Aerohalor, containing potassium penicillin G; Abbott Laboratories, Inc., 14th and Sheridan Road, North Chicago, Illinois 60064 (NDA 60-105).

Preparations containing penicillin are subject to the antibiotic procedures pursuant to section 507 of the Federal Food, Drug, and Cosmetic Act.

The Academy commented that penicillin may, in some instances, be effective in treating a variety of pulmonary infections; however, penicillin is a sensitizing drug and since inhalation therapy has been accompanied by severe allergic reactions, there is little reason to keep the drug in the therapeutic armamentarium.

The Food and Drug Administration has considered the Academy's report, as well as other available information, and concludes that there is a lack of substantial evidence that the effectiveness of penicillin for inhalation therapy is sufficient to justify its use in view of the known serious hazards associated with such use.

Accordingly, the Commissioner of Food and Drugs intends to initiate proceedings to amend the antibiotic drug regulations (21 CFR Part 146) in order to delete from the list of drugs acceptable for certification or release the above listed drug and any similar drug for inhalation therapy in man.

Prior to initiating such action, however, the Commissioner invites all in-

interested persons who might be adversely affected by removal of these drugs from the market to submit pertinent data bearing on the proposal within 30 days following the date of publication of this announcement in the FEDERAL REGISTER. To be acceptable for consideration in support of the effectiveness of a drug, any such data must be previously unsubmitted, well-organized, and include data from adequate and well-controlled clinical investigations (identified for ready review) as described in § 130.12(a) (5) of the regulations published in the FEDERAL REGISTER of May 8, 1970 (35 F.R. 7250). Carefully conducted and documented clinical studies obtained under uncontrolled or partially controlled situations are not acceptable as a sole basis for the approval of claims of effectiveness, but such studies may be considered on their merits for corroborative support of efficacy and evidence of safety.

This announcement of the proposed action and implementation of the Academy's report for this drug is made to give notice to persons who might be adversely affected by removal of this or similar drugs from the market.

A copy of the Academy's report has been furnished to the firm referred to above. Any other interested person may obtain a copy by request to the Food and Drug Administration, Press Relations Office (CE-200), 200 C Street SW., Washington, D.C. 20204.

Communications forwarded in response to this announcement should be identified with the reference number DESI 60105 and be directed to the attention of the Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs, Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20852.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 507, 52 Stat. 1050-51, as amended; 59 Stat. 463, as amended; 21 U.S.C. 352, 357) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: May 5, 1971.

SAM D. FINE,
Associate Commissioner
for Compliance.

[FR Doc.71-8719 Filed 6-21-71; 8:46 am]

MORTON INTERNATIONAL, INC.

Notice of Filing of Petition for Food Additives

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409(b) (5), 72 Stat. 1786; 21 U.S.C. 348(b) (5)), notice is given that a petition (FAP 1A2688) has been filed by Morton International, Inc., 110 North Wacker Drive, Chicago, Ill. 60606, proposing the issuance of a food additive regulation (21 CFR Part 121) to provide for the safe use of glycine as a flavor-masking agent for saccharin in sugar substitutes for table use.

Dated: June 16, 1971.

VIRGIL O. WODICKA,
Director, Bureau of Foods.

[FR Doc.71-8716 Filed 6-21-71; 8:46 am]

MONSANTO CO.

Notice of Filing of Petition for Food Additives

Pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 409(b) (5), 72 Stat. 1786; 21 U.S.C. 348(b) (5)), notice is given that a petition (FAP 1B2685) has been filed by Monsanto Co., 1101 17th Street NW., Washington, D.C. 20036, proposing that § 121.2502 *Nylon resins* (21 CFR 121.2502) be amended to provide for the safe use in food-contact articles of a new nylon resin manufactured from nylon 66 resins and resins obtained by the condensation of hexamethylene diamine and terephthalic acid.

Dated: June 16, 1971.

VIRGIL O. WODICKA,
Director, Bureau of Foods.

[FR Doc.71-8700 Filed 6-21-71; 8:45 am]

[DESI 10761]

CERTAIN ANTISEBORRHEIC DRUGS CONTAINING CADMIUM SULFIDE FOR TOPICAL USE

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated a report received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on Capsebion Suspension containing cadmium sulfide, marketed by The Dow Chemical Co., Box 10, Zionsville, Indiana 46077 (NDA 10-761).

The drug is regarded as a new drug. The effectiveness classification and marketing status are described below.

A. *Effectiveness classification.* The Food and Drug Administration has considered the Academy's report, as well as other available evidence, and concludes that cadmium sulfide is probably effective for the treatment of seborrheic dermatitis of the scalp.

B. *Marketing status.* 1. The indication for which the drug is described in paragraph A above as probably effective may continue to be used for 12 months following the date of this publication to allow additional time within which holders of previously approved applications or persons marketing such drug without approval may obtain and submit to the Food and Drug Administration data to provide substantial evidence of effectiveness. In addition, data including adequate toxicity studies on cadmium sulfide should be presented, because cadmium poisoning can be subtle.

2. At the end of the 12-month period, any such data will be evaluated to determine whether there is substantial evidence of effectiveness of the drug for such uses. The conclusions concerning the drug will be published in the FEDERAL REGISTER. If no studies have been undertaken or if the studies do not provide substantial evidence of effectiveness, procedures will be initiated to withdraw approval of the new drug application for

the drug, pursuant to the provisions of section 505(e) of the Federal Food, Drug, and Cosmetic Act. Withdrawal of approval of the application will cause any such drug on the market to be a new drug for which an approval is not in effect.

3. Within 60 days from publication hereof in the FEDERAL REGISTER, the holder of any approved new drug application for such drug is requested to submit a supplement to his application to provide for revised labeling as needed, which, taking into account the comments of the Academy, furnishes adequate information for safe and effective use of the drug, is in accord with the guidelines for uniform labeling published in the FEDERAL REGISTER of February 6, 1970 (21 CFR 3.74), and recommends use of the drug for the probably effective indication as follows:

INDICATIONS

For the treatment of seborrheic dermatitis of the scalp.

The above named holder of the new-drug application for this drug has been mailed a copy of the NAS-NRC report. Any interested person may obtain a copy of this report by writing to the office named below.

Communications forwarded in response to this announcement should be identified with the reference number DESI 10761 and be directed to the attention of the appropriate office named below and addressed (unless otherwise specified) to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20852:

Supplements (Identify with NDA number):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.

Original new-drug applications: Office of Scientific Evaluation (BD-100), Bureau of Drugs.

Other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs.

Requests for NAS-NRC reports: Press Relations Office (CE-200), Food and Drug Administration, 200 C Street SW., Washington, D.C. 20204.

This notice is issued pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: May 6, 1971.

SAM D. FINE,
Associate Commissioner
for Compliance.

[FR Doc.71-8701 Filed 6-21-71; 8:45 am]

[DESI 10837]

CERTAIN ANTICHOLINERGIC DRUGS Drugs for Human Use; Drug Efficacy Study Implementation

Certain anticholinergic drugs containing prochlorperazine maleate and isopropamide iodide; oxyphenyclimine

hydrochloride and meprobamate; oxyphenylcyclimine hydrochloride and hydroxyzine hydrochloride; tridihexethyl chloride and meprobamate; and propantheline bromide and thiopropazate hydrochloride.

The Food and Drug Administration has evaluated reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following anticholinergic and tranquilizing drugs for oral use:

1. Combid Spansule Capsules, containing prochlorperazine maleate and isopropamide iodide; Smith, Kline, and French Laboratories, 1500 Spring Garden Street, Philadelphia, Pa. 19101 (NDA 11-162).

2. Daritran Tablets, containing oxyphenylcyclimine hydrochloride and meprobamate; Chas. Pfizer and Co., 235 East 42d Street, New York, N.Y. 10017 (NDA 12-070).

3. Enarax 5 Tablets and Enarax 10 Tablets, containing oxyphenylcyclimine hydrochloride and hydroxyzine hydrochloride; Chas. Pfizer and Co. (NDA 11-784).

4. Milpath-200 Tablets and Milpath-400 Tablets, containing meprobamate and tridihexethyl chloride; Wallace Laboratories, Half Acre Road, Cranbury, N.J. 08512 (NDA 11-043).

5. Pathibamate-200 Tablets and Pathibamate-400 Tablets, containing tridihexethyl chloride and meprobamate; Lederle Laboratories Division, American Cyanamid Co., Pearl River, N.Y. 10965 (NDA 10-837).

6. Pro-Banthine with Dartal Tablets, containing propantheline bromide and thiopropazate hydrochloride; G. D. Searle and Co., Post Office Box 5110, Chicago, Ill. 60680 (NDA 11-368).

Such drugs are regarded as new drugs (21 U.S.C. 321(p)). The effectiveness classification and marketing status are described below.

A. Effectiveness classification. The Food and Drug Administration has considered the Academy's reports, as well as other available evidence, and concludes that these drugs are possibly effective as adjunctive therapy in peptic ulcer and in the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis, functional gastrointestinal disorders); functional diarrhea; drug induced diarrhea; ulcerative colitis, and urinary bladder spasm and urethral spasm (i.e., smooth muscle spasm). In addition, oxyphenylcyclimine and meprobamate preparations are possibly effective for dysmenorrhea.

These drugs lack substantial evidence of effectiveness for their other labeled indications.

B. Marketing status. 1. Within 60 days of the date of publication of this announcement in the FEDERAL REGISTER, the holder of any approved new drug application for which a drug is classified in paragraph A above as lacking substantial evidence of effectiveness is requested to submit a supplement to his application, as needed to provide for revised labeling which deletes those indications for which substantial evidence of effectiveness is lacking. Such a supplement

should be submitted under the provisions of § 130.9 (d) and (e) of the new drug regulations (21 CFR 130.9 (e) and (d)) which permit certain changes to be put into effect at the earliest possible time, and the revised labeling should be put into use within the 60-day period. Failure to do so may result in a proposal to withdraw approval of the new drug application.

2. If any such preparation is on the market without an approved new drug application, its labeling should be revised if it includes those claims for which substantial evidence of effectiveness is lacking as described in paragraph A above. Failure to delete such indications and put the revised labeling into use within 60 days after the date of publication hereof in the FEDERAL REGISTER may cause the drug to be subject to regulatory proceedings.

3. The notice "Conditions for Marketing New Drugs Evaluated in Drug Efficacy Study" published in the FEDERAL REGISTER July 14, 1970 (35 F.R. 11273) describes in paragraphs (d), (e), and (f) the marketing status of a drug labeled with those indications for which it is regarded as possibly effective.

A copy of the Academy's report has been furnished to each firm referred to above. Any other interested person may obtain a copy by request to the Food and Drug Administration, Press Relations Office (CE-200), 200 C Street SW., Washington, D.C. 20204.

Communications forwarded in response to this announcement should be identified with the reference number DESI 10837, directed to the attention of the appropriate office listed below, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Md. 20852:

Supplements (Identify with NDA number):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.

Original new drug applications: Office of Scientific Evaluation (BD-100), Bureau of Drugs.

All other communications regarding this announcement: Drug Efficacy Study Implementation Project Office (BD-5), Bureau of Drugs.

This notice is issued pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: May 3, 1971.

CHARLES C. EDWARDS,
Commissioner of Food and Drugs.

[FR Doc.71-8702 Filed 6-21-71; 8:45 am]

[DESI 12329]

GUANETHIDINE SULFATE

Drugs for Human Use; Drug Efficacy Study Implementation

The Food and Drug Administration has evaluated a report received from the National Academy of Sciences-National Research Council, Drug Efficacy Study

Group, on Ismelin Sulfate Tablets containing guanethidine sulfate; marketed by Ciba Pharmaceutical Co., 556 Morris Avenue, Summit, New Jersey 07901 (NDA 12-329).

The drug is regarded as a new drug (21 U.S.C. 321(p)). Supplemental new drug applications are required to revise the labeling in and to update previously approved applications providing for such drug. A new drug application is required from any person marketing such drug without approval.

The Food and Drug Administration is prepared to approve new drug applications and supplements to previously approved new drug applications under conditions described in this announcement.

A. Effectiveness classification. The Food and Drug Administration has considered the Academy's report, as well as other available evidence, and concludes that guanethidine sulfate is effective for:

a. The treatment of severe hypertension either alone or as an adjunct.

b. The treatment of renal hypertension, including that secondary to pyelonephritis, renal amyloidosis, and renal artery stenosis.

B. Form of drug. Guanethidine sulfate preparations are in tablet form suitable for oral administration.

C. Labeling conditions. 1. The label bears the statement, "Caution: Federal law prohibits dispensing without prescription."

2. The drug is labeled to comply with all requirements of the Act and regulations. Its labeling bears adequate information for safe and effective use of the drug and is in accord with the guidelines for uniform labeling published in the FEDERAL REGISTER of February 6, 1970. The "Indications" section is as follows:

INDICATIONS

1. For the treatment of severe hypertension either alone or as an adjunct.

2. For the treatment of renal hypertension, including that secondary to pyelonephritis, renal amyloidosis, and renal artery stenosis.

D. Previously approved applications.

1. Each holder of a "deemed approved" new drug application (i.e., an application which became effective on the basis of safety prior to October 10, 1962) for such drug is requested to seek approval of the claims of effectiveness and bring the application into conformance by submitting supplements containing:

a. Revised labeling as needed to conform with the labeling conditions described herein for the drug and complete current container labeling, unless recently submitted.

b. Updating information as needed to make the application current.

2. Such supplements should be submitted within the following time periods after the date of publication of this announcement in the FEDERAL REGISTER.

a. 60 days for revised labeling—the supplement should be submitted under the provisions of § 130.9 (d) and (e) of the new drug regulations (21 CFR 130.9) which permit certain changes to be put into effect at the earliest possible time.

b. 60 days for updating information.

3. Marketing of the drug may continue until the supplemental applications submitted in accord with the preceding subparagraphs 1 and 2 are acted upon, provided that within 60 days after the date of this publication, the labeling of this preparation shipped within the jurisdiction of the Act is in accord with the labeling conditions described in this announcement.

E. *New applications.* 1. Any other person who distributes or intends to distribute such drug which is intended for the conditions of use for which it has been shown to be effective, as described under paragraph A above, should submit a new drug application containing full information required by the new drug application form FD-356H (21 CFR 130.4 (c)). Such applications should include proposed labeling which is in accord with the labeling conditions described herein.

2. Distribution of any such preparation currently on the market without an approved new drug application may be continued provided that:

a. Within 60 days from the date of publication of this announcement in the FEDERAL REGISTER, the labeling of such preparation shipped within the jurisdiction of the Act is in accord with the labeling conditions described herein.

b. The manufacturer, packer, or distributor of such drug submits, within 60 days from the date of this publication, a new drug application to the Food and Drug Administration.

c. The applicant submits additional information that may be required for the approval of the application within a reasonable time as specified in a written communication from the Food and Drug Administration.

d. The application has not been ruled incomplete or unapprovable.

F. *Unapproved use or form of drug.* 1. If the article is marketed in any other form or is labeled or advertised for use in any condition other than those provided for in this announcement, it may be regarded as an unapproved new drug subject to regulatory proceedings until such form or use is approved in a new drug application, or is otherwise in accord with this announcement.

A copy of the Academy's report has been furnished to each firm referred to above. Any other interested person may obtain a copy by request to the appropriate office named below.

Communications forwarded in response to this announcement should be identified with the reference number DESI 12329, directed to the attention of the following appropriate office, and addressed (unless otherwise specified) to the Food and Drug Administration, 5600 Fishers Lane, Rockville, Maryland 20852:

Supplements (identify with NDA number):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.

Original new drug applications (identify as such):
Office of Scientific Evaluation (BD-100),
Bureau of Drugs.

Requests for NAS-NRC report: Press Relations
Office (CE-200), Food and Drug
Administration, 200 O Street SW., Wash-
ington, D.C. 20204.

All other communications regarding this announcement: Drug Efficacy Study Imple-

mentation Project Office (BD-5), Bureau
of Drugs.

This notice is issued pursuant to the provisions of the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-53, as amended; 21 U.S.C. 352, 355) and under the authority delegated to the Commissioner of Food and Drugs (21 CFR 2.120).

Dated: May 5, 1971.

SAM D. FINE,
Associated Commissioner
for Compliance.

[FR Doc.71-8703 Filed 6-21-71;8:45 am]

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. D-71-111]

ACTING AREA DIRECTOR, SAN FRANCISCO AREA OFFICE, REGION IX (SAN FRANCISCO)

Designation

The officials appointed to the following listed positions in the San Francisco Area Office, Region IX (San Francisco), are hereby designated to serve as Acting Area Director, San Francisco Area Office, Region IX (San Francisco) during the absence of the Area Director, with all powers, functions, and duties redelegated or assigned to the Area Director: *Provided*, That no official is authorized to serve as Acting Area Director unless all other officials whose titles precede his in this designation are unable to act by reason of absence:

1. Deputy Area Director;
2. Director, Production Division;
3. Director, Housing Services and Property Management Division;
4. Area Counsel.

(Delegation and redelegation of authority to take final action with respect to certain positions and employees effective as of May 4, 1969)

Effective as of the 21st day of September 1970.

ANDREW J. BELL III,
Acting Regional Administrator,
Region IX.

[FR Doc.71-8709 Filed 6-21-71;8:46 am]

[Docket No. D-71-112]

ACTING AREA DIRECTOR, LOS ANGELES AREA OFFICE, REGION IX (SAN FRANCISCO)

Designation

The officials appointed to the following listed positions in the Los Angeles Area Office, Region IX (San Francisco), are hereby designated to serve as Acting Area Director, Los Angeles Area Office, Region IX (San Francisco) during the absence of the Area Director, with all powers, functions, and duties redelegated or assigned to the Area Director: *Provided*, That no official is authorized to serve as Acting Area Director unless all other officials whose titles precede his in this designation are unable to act by reason of absence:

1. Deputy Area Director;
2. Director, Production Division;
3. Director, Housing Services and Property Management Division;
4. Area Counsel.

This designation supersedes the designation of Acting Area Director, Southwest Area Office at Los Angeles, at 34 F.R. 14039, September 4, 1969.

(Delegation and redelegation of authority to take final action with respect to certain positions and employees effective as of May 4, 1969)

Effective as of the 21st day of September 1970.

ANDREW J. BELL III,
Acting Regional Administrator,
Region IX.

[FR Doc.71-8710 Filed 6-21-71;8:46 am]

ATOMIC ENERGY COMMISSION

URANIUM HEXAFLUORIDE

Charges, Enriching Services, Specifications, and Packaging; Revisions

The U.S. Atomic Energy Commission (AEC) hereby announces revisions to the notice entitled, "Uranium Hexafluoride: Base Charges, Use Charges, Special Charges, Table of Enriching Services, Specifications, and Packaging", as published in the FEDERAL REGISTER on November 29, 1967 (32 F.R. 16289), and as amended in 35 F.R. 13547, August 25, 1970, and in 36 F.R. 4563, March 9, 1971 (referred to herein as the notice).

1. Table 4 of the notice is revised to read as follows:

TABLE 4.—CHARACTERISTICS OF AEC UF₆ CONTAINERS

Container		Material of construction	Nominal length ¹ (ins.)	Nominal diameter (ins.)	Approximate tare weight (lbs.)	Capacity (lbs. UF ₆)	Minimum loading (lbs. UF ₆)
Type	Model No.						
14-ton	48F	Steel	150	48	5,200	27,030	*21,000
10-ton	48A	do	121	48	4,500	21,030	*14,000
2.5-ton	30A	do	82	30	1,400	4,950	*2,300
2.5-ton	30B	do	82	30	1,400	5,020	*2,300
12-inch (MD)	12A	Monel or nickel	54	12	155	460	65
8-inch	8A	do	57	8	120	255	65
5-inch	5A	do	36	5	55	55	11
Harshaw	2S	do	11	3.5	4	4.9	1
1.5-inch	1S	do	12	1.3	2	1	45 grams
Hoke tube	HT	Nickel	8	0.3	1	15 grams	1 gram

¹ Overall length with valve cap (if any) in place.

* Minimum quantity which permits safe handling with UF₆ in liquid state.

* For receipts by AEC—Upon request lesser quantities of product may be put in cylinders.